Genmab AS (GMAB) reports a 29% revenue increase and strategic moves in its product pipeline, despite challenges in ...

Assetmark Inc. boosted its stake in shares of Genmab A/S (NASDAQ:GMAB – Free Report) by 16.2% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 82,629 shares of ...

Deutsche Bank lowered the firm’s price target on Genmab (GMAB) to DKK 2,250 from DKK 2,500 and keeps a Buy rating on the shares.

Hello, and welcome to Genmab's Financial Results Conference Call for the First Nine Months of 2024. As a reminder, this conference call is being recorded. During this telephone conference, you may ...

Genmab reported impressive earnings with significant revenue growth driven by its key products, despite rising expenses.

It has been roughly eight months since my last Genmab (GMAB) article, where I highlighted the company's robust pipeline progress, strategic partnerships, and a strong 2023 performance, led by ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Genmab (GMAB – Research Report). The company’s shares closed yesterday at $22.33. Goonewardene covers ...

In this article, we are going to take a look at where Genmab (NASDAQ:GMAB) stands against other most profitable growth stocks to invest in. After the September inflation report, the market did ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good afternoon. Thank you for attending the Babcock & Wilcox ...